2021
Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy
Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalEndometrioid endometrial cancerVaginal brachytherapyPMMR patientsOverall survivalEEC patientsEndometrial cancerExact testThree-year recurrence-free survivalEarly-stage endometrial cancerCox proportional hazards regressionPoor recurrence-free survivalAdjuvant vaginal brachytherapyThree-year OSMultivariable Cox regressionLympho-vascular invasionSignificant prognostic variablesProportional hazards regressionLog-rank testKaplan-Meier estimatesDeficient mismatch repairMismatch repair statusFisher's exact testMismatch repair deficiencyDMMR status
2015
PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors
Yang HP, Meeker A, Guido R, Gunter MJ, Huang GS, Luhn P, d’Ambrosio L, Wentzensen N, Sherman ME. PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes & Control 2015, 26: 1729-1736. PMID: 26376893, PMCID: PMC4628559, DOI: 10.1007/s10552-015-0666-5.Peer-Reviewed Original ResearchConceptsEndometrial cancer risk factorsCancer risk factorsEndometrial cancer tissuesEndometrial tissueRisk factorsBenign endometriumNSAID usePTEN lossEndometrial cancerEndometrial glandsPTEN expressionExact testCancer tissuesPopulation-based case-control studyBenign endometrial samplesBenign endometrial tissuesMost risk factorsHuman endometrial tissueCase-control studyFisher's exact testEndometrial hyperplasiaEndometrial carcinomaEndometrial samplesEutopic endometriumImmunohistochemical study
2010
Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer
Huang GS, Brouwer-Visser J, Ramirez MJ, Kim CH, Hebert TM, Lin J, Arias-Pulido H, Qualls CR, Prossnitz ER, Goldberg GL, Smith HO, Horwitz SB. Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer. Clinical Cancer Research 2010, 16: 2999-3010. PMID: 20404007, PMCID: PMC2887721, DOI: 10.1158/1078-0432.ccr-09-3233.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, PhytogenicBiomarkers, TumorCell Line, TumorCell ProliferationDisease-Free SurvivalDrug Resistance, NeoplasmFemaleGene Knockdown TechniquesHumansInsulin-Like Growth Factor IIOvarian NeoplasmsPaclitaxelPhosphorylationPrognosisProto-Oncogene Proteins c-aktPyrimidinesPyrrolesReceptor, IGF Type 1RNA, Small InterferingSignal TransductionConceptsEpithelial ovarian tumorsInsulin-like growth factorDisease-free survivalOvarian carcinoma cellsOvarian tumorsTaxol resistancePathway inhibitionIGF2 expressionOvarian cancerCarcinoma cellsExact testReduced disease-free survivalHuman epithelial ovarian tumorsCandidate prognostic biomarkerDrug-resistant ovarian carcinoma cellsUpregulation of IGF2Fisher's exact testIGF2 protein expressionOvarian cancer cellsDrug-resistant phenotypeHigh IGF2 expressionIGF receptor inhibitorsPathologic factorsTaxol-resistant cell linesCox regression
2007
Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma
Huang GS, Chiu LG, Gebb JS, Gunter MJ, Sukumvanich P, Goldberg GL, Einstein MH. Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma. Gynecologic Oncology 2007, 107: 513-517. PMID: 17935762, PMCID: PMC2696225, DOI: 10.1016/j.ygyno.2007.08.060.Peer-Reviewed Original ResearchConceptsDeep myometrial invasionCA125 elevationExtrauterine diseasePrognostic factorsUterine carcinosarcomaPreoperative CA125CA125 levelsCA125 measurementMyometrial invasionPoor survivalExact testCox proportional hazards modelClinicopathologic prognostic factorsEstrogen receptor positivityIndependent prognostic factorManagement of patientsUnivariate survival analysisUseful serum markerPearson's chi-square testProportional hazards modelFisher's exact testChi-square testSerous histologyConsecutive patientsReceptor positivity
2004
Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index
O'Hanlan KA, Huang GS, Lopez L, Garnier AC. Selective incorporation of total laparoscopic hysterectomy for adnexal pathology and body mass index. Gynecologic Oncology 2004, 93: 137-143. PMID: 15047227, DOI: 10.1016/j.ygyno.2003.12.020.Peer-Reviewed Original ResearchConceptsTotal laparoscopic hysterectomyBody mass indexAdnexal pathologyUrological injuriesLaparoscopic hysterectomyBMI groupsMass indexOvarian carcinomaExact testRecurrent breast cancerMean surgery durationMean complication rateFisher's exact testObstructive adhesionsEarly complicationsHospital stayStage IAChart abstractionComplication rateNodal yieldBlood lossOvarian pathologyMucinous cystadenomaPelvic massMean age